• No products in the list

KRAS StripAssay

Short description

The KRAS StripAssay® is a revolutionary diagnostic tool designed for the targeted treatment of metastatic colorectal cancer (mCRC). Utilizing polymerase chain reaction (PCR) technology, the assay identifies crucial KRAS gene mutations that can render anti-EGFR therapies ineffective. By aiding clinicians in stratifying patients for therapies like cetuximab and panitumumab, it plays a pivotal role in personalized medicine. With a streamlined three-step procedure involving DNA isolation, PCR amplification, and hybridization, this assay offers a quick yet accurate methodology for optimizing mCRC treatment plans.

Product highlights

  • Precision Stratification
  • Quick Diagnosis
  • Targeted Treatment
  • PCR Technology
  • Comprehensive Coverage
  • User-Friendly

Ask for a quote

KRAS StripAssay



Instructions for Use

Brochure StripAssays


For any missing information or if you require additional details, please do not hesitate to contact us. 

Specifications of the KRAS StripAssay

Optimizing Anti-EGFR Therapies with KRAS StripAssays®

The landscape of metastatic colorectal cancer (mCRC) treatment has seen significant progress with the introduction of monoclonal antibody (mAb) therapies targeting the epidermal growth factor receptor (EGFR). Yet, the success of such treatments can be undermined by specific mutations in the KRAS gene. These mutations result in the permanent activation of vital cellular signaling pathways, making anti-EGFR therapies ineffective. KRAS StripAssays® offer a targeted solution to this challenge by assisting clinicians in stratifying patients for anti-EGFR therapies like cetuximab and panitumumab.

The Role of KRAS in mCRC Therapies

The KRAS gene plays an integral role in the MAPK signaling pathway, which is downstream of the EGFR. Mutations in this gene activate the pathway permanently, effectively canceling out the inhibitory effects of anti-EGFR mAbs. This makes genetic screening to identify such mutations an indispensable step in determining the suitability of mCRC patients for anti-EGFR therapies.

Intended Use and Methodology

Designed for human in vitro diagnostics, the KRAS StripAssay® employs polymerase chain reaction (PCR) to detect these pivotal mutations. The methodology is streamlined, involving DNA isolation, PCR amplification using biotinylated primers, and hybridization of these amplified products to a test strip embedded with allele-specific oligonucleotide probes. This rigorous approach ensures precise and reliable mutation detection, crucial for shaping the course of treatment.

Clinical Relevance and Impact

The presence of KRAS mutations is a significant factor in predicting the lack of response to anti-EGFR mAb therapies in mCRC patients. KRAS StripAssays® are not just diagnostic tools; they are enablers in the advancement of personalized medicine for mCRC treatment. By offering an efficient and comprehensive way to identify these genetic mutations, the assay is ushering us towards an era where treatments are increasingly personalized, thereby heightening the probability of successful outcomes.

KRAS StripAssays® serve a critical function in shaping mCRC treatment strategies. They offer clinicians the scientific accuracy needed to make informed decisions, ensuring that patients receive therapies most likely to succeed. With its targeted approach, the KRAS StripAssay® is not only a cornerstone in modern diagnostics but also a game-changer in the effective management of mCRC.

Components of the KRAS StripAssay
  • Amplification Mix (500 µl)
  • Taq Dilution Buffer (500 µl)
  • Taq DNA Polymerase (75 U)
  • DNAT (1.5 ml)
  • Typing Trays (3)
  • Teststrips (20)
  • Hybridization Buffer (25 ml)
  • Wash Solution A (80 ml)
  • Wash Solution B (80 ml)
  • Conjugate Solution (25 ml)
  • Color Developer (25 ml)
  • Collector™ Sheet

Explore Related Items